公开(公告)号：EP3418378A1

公开(公告)日：2018-12-26

申请号：EP17177514.1

申请日：2017-06-22

Applicant: HI-STEM gGmbH Im Deutschen Krebsforschungszentrum DKFZ

Inventor： Trumpp, Dr. Andreas ,  Frank, Edenhofer ,  Thier, Marc

IPC: C12N5/0797 ,  C12N5/079 ,  C12N5/0793

CPC classification number: C12N5/0618 ,  C12N5/0619 ,  C12N5/0622 ,  C12N5/0623 ,  C12N2501/105 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/155 ,  C12N2501/235 ,  C12N2501/41 ,  C12N2501/415 ,  C12N2501/60 ,  C12N2501/602 ,  C12N2501/604 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2506/11 ,  C12N2506/115 ,  C12N2506/1307 ,  C12N2510/00

Abstract: This invention relates to a novel approach for the generation of human induced neural border stem cells (iNBSCs) by the direct conversion of somatic cells (peripheral blood, skin biopsies) and to novel uses of such cells, including the differentiation of these stem cells into cell types of the CNS and the neural crest lineages, and the uses of such cells.

公开(公告)号：EP2694642B8

公开(公告)日：2018-10-17

申请号：EP12712670.4

申请日：2012-04-10

Applicant: Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Centre National de la Recherche Scientifique (C.N.R.S.) ,  Université de Montpellier

Inventor： PRIEUR, Alexandre ,  MILHAVET, Ollivier ,  LEMAITRE, Jean-Marc ,  LAPASSET, Laure

IPC: C12N5/074 ,  A61K35/12

CPC classification number: C12N5/0696 ,  A61K35/12 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/605 ,  C12N2501/606 ,  C12N2501/608 ,  C12N2506/1307 ,  C12N2510/00

Abstract: The invention relates to a method for reprogramming cells from aged donors or senescent cells to pluripotent cells that have lost marks of senescence. In particular, the invention relates to an ex vivo method for preparing induced pluripotent stein cells (iPSCs) from a target cell population comprising cells from aged donors or senescent cells, said method comprising the steps of culturing said target cell population tinder appropriate conditions for reprogramming said cells into iPSCs, wherein said appropriate conditions comprises increasing expression in said target cells, of at least the following reprogramming factors: Oct4, Klf4, Sox2, Myc, Lin28 and, optionally Nanog.

公开(公告)号：EP2852671B1

公开(公告)日：2018-08-22

申请号：EP13794196.9

申请日：2013-05-21

Applicant: The Regents of the University of California

Inventor： DOWDY, Steven, F. ,  YOSHIOKA, Naohisa

IPC: C12N15/40 ,  C12N15/85 ,  C12N5/10 ,  C12N5/074

CPC classification number: C12N5/0696 ,  C07K14/4702 ,  C07K14/4705 ,  C12N9/127 ,  C12N15/86 ,  C12N2501/60 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/605 ,  C12N2501/606 ,  C12N2506/1307 ,  C12N2770/36122 ,  C12N2770/36143 ,  C12N2840/206 ,  G01N33/56966

Abstract: The disclosure provides methods and compositions useful for obtaining induced stem cells, methods of making and use thereof.

公开(公告)号：EP3317405A1

公开(公告)日：2018-05-09

申请号：EP16820787.6

申请日：2016-07-01

Applicant: Beihao Stem Cell and Regenerative Medicine Research Institute Co., Ltd. ,  Peking University

Inventor： DENG, Hongkui ,  LI, Xiang ,  ZUO, Xiaohan

IPC: C12N5/0793 ,  A61K35/30 ,  A61P25/00 ,  A61P25/14 ,  A61P25/28

CPC classification number: A61K35/30 ,  A61K9/0019 ,  C12N5/00 ,  C12N5/0607 ,  C12N5/0619 ,  C12N2501/01 ,  C12N2501/15 ,  C12N2506/1307 ,  C12N2506/1353 ,  C12N2506/1369 ,  C12N2506/1384 ,  C12N2506/1392

Abstract: Cocktails of chemical inducers of neuron-like properties (CINP) is provided, which includes cAMP agonists, neurogenic small molecules, glycogen synthase kinase inhibitors, TGFβ receptor inhibitors, and BET family bromodomain inhibitors and optionally, a selective inhibitor of ROCK or p38 MAPK. These cocktails are used in a method of inducing neuron-like properties in partially or completely differentiated non-neuronal cells. The method includes contacting cells of a first type (non-neuronal) with the CINPs for a sufficient period of time to result in reprogramming the cell into cells of a second type having neuron-like characteristics (CiNs). Isolated chemically induced neurons (CiNs) can be used in a number of applications, including but not limited to cell therapy.

公开(公告)号：EP2736357B1

公开(公告)日：2018-05-02

申请号：EP12817489.3

申请日：2012-07-26

Applicant: The Curators Of The University Of Missouri

Inventor： FORGACS, Gabor ,  MARGA, Francoise ,  JAKAB, Karoly, Robert

IPC: A23L13/00 ,  A23L13/60 ,  C12N5/00 ,  C12N5/077 ,  C12N5/071

CPC classification number: A23L13/00 ,  A23L13/03 ,  C12M21/08 ,  C12N5/0062 ,  C12N5/0697 ,  C12N2502/1347 ,  C12N2502/28 ,  C12N2506/1307 ,  C12N2533/76

Abstract: Provided are engineered meat products formed as a plurality of at least partially fused layers, wherein each layer comprises at least partially fused multicellular bodies comprising non-human myocytes and wherein the engineered meat is comestible. Also provided are multicellular bodies comprising a plurality of non-human myocytes that are adhered and/or cohered to one another; wherein the multicellular bodies are arranged adjacently on a nutrient-permeable support substrate and maintained in culture to allow the multicellular bodies to at least partially fuse to form a substantially planar layer for use in formation of engineered meat. Further described herein are methods of forming engineered meat utilizing said layers.

公开(公告)号：EP3159354A4

公开(公告)日：2018-03-07

申请号：EP15811420

申请日：2015-06-22

Applicant: TOAGOSEI CO LTD ,  UNIV KEIO ,  UNIV NAGOYA NAT UNIV CORP

Inventor： YOSHIDA TETSUHIKO ,  BAILEYKOBAYASHI NAHOKO ,  NIWA MIKIO ,  KUDO JUN ,  IZUMIYAMA TOMOHIRO ,  SAWADA MAKOTO

IPC: C07K7/06 ,  A61K38/00 ,  A61P43/00 ,  C07K14/00 ,  C12N5/0735

CPC classification number: C12N5/0696 ,  A61K38/00 ,  C07K7/06 ,  C07K14/00 ,  C12N2501/40 ,  C12N2506/1307

Abstract: Provided are a synthetic peptide that induces the reprogramming of a differentiated cell, a reprogramming-inducing pharmaceutical composition that contains this synthetic peptide, and a method for producing an undifferentiated cell from a differentiated cell using this synthetic peptide. The peptide provided by the present invention is a synthetic peptide having a reprogramming-inducing peptide sequence formed of the amino acid sequence given by SEQ ID NO: 1 or a modified amino acid sequence thereof. The method for producing an undifferentiated cell provided by the present invention includes inducing the reprogramming of a target cell by culturing a cell culture which contains the target cell and to which the synthetic peptide has been supplied.

公开(公告)号：EP3118306A4

公开(公告)日：2018-02-14

申请号：EP15758550

申请日：2015-03-09

Applicant: UNIST (ULSAN NAT INSTITUTE OF SCIENCE AND TECHNOLOGY)

Inventor： KIM JEONG BEOM

IPC: A61K38/17 ,  A61K35/30 ,  A61P25/00 ,  C12N5/02 ,  C12N5/079 ,  C12N15/85

CPC classification number: C12N5/0622 ,  A61K35/17 ,  A61K35/28 ,  A61K35/30 ,  A61K35/33 ,  A61K35/38 ,  A61K35/51 ,  A61K38/1709 ,  C12N15/85 ,  C12N2500/38 ,  C12N2501/01 ,  C12N2501/115 ,  C12N2501/135 ,  C12N2501/395 ,  C12N2501/60 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2506/1307 ,  C12N2510/00 ,  G01N33/5058 ,  G01N2333/4703 ,  G01N2800/285

Abstract: The present invention relates to a composition for inducing direct transdifferentiation into oligodendrocyte progenitor cells (OPCs) from somatic cells, the composition containing at least one protein selected from the group consisting of direct transdifferentiation factors OCT4, SOX1, SOX2, SOX10, OLIG2, NKX2.2, and NKX6.2, a nucleic acid molecule coding the protein, or a vector including the nucleic acid molecule introduced thereinto; a pharmaceutical composition for preventing or treating spinal cord injuries or demyelination diseases; a cell therapy agent for preventing or treating spinal cord injuries or demyelination diseases; a cell therapy agent for treating spinal cord injuries or demyelination diseases; a composition for screening drugs for the treatment of spinal cord injuries or demyelination diseases; a 3D printing biomaterial composition for manufacturing artificial tissues for the treatment of spinal cord injuries or demyelination diseases; and a method for direct transdifferentiation into oligodendrocyte progenitor cells from somatic cells. According to the present invention, the oligodendrocyte progenitor cells are prepared from somatic cells through direct transdifferentiation, and thus can be favorably utilized for the treatment of spinal cord injuries and demyelination diseases.

公开(公告)号：EP3165603A4

公开(公告)日：2018-01-10

申请号：EP15815940

申请日：2015-07-03

Applicant: UNIV SAITAMA MEDICAL

Inventor： MATSUMOTO MASAHITO ,  OKAZAKI YASUSHI ,  SUGAHARA IZUMI

IPC: C12N5/10 ,  C12N15/09

CPC classification number: C12N5/0676 ,  C12N2501/60 ,  C12N2506/02 ,  C12N2506/1307 ,  C12N2506/14 ,  C12N2506/25 ,  C12N2506/30 ,  C12N2510/00 ,  C12N2799/06

Abstract: A method for producing pancreatic endocrine cells, the method including introducing one or more genes of a GLIS family or one or more gene products thereof and a Neurogenin3 gene or one or more gene products thereof into somatic cells.

公开(公告)号：EP2499241B1

公开(公告)日：2018-01-10

申请号：EP10830566.5

申请日：2010-11-08

Applicant: The J. David Gladstone Institutes

Inventor： HUANG, Yadong ,  RING, Karen Lee

IPC: C12N5/0797

CPC classification number: C12N5/0623 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/602 ,  C12N2501/91 ,  C12N2502/99 ,  C12N2506/1307 ,  C12N2510/00

Abstract: The present disclosure provides methods of generating neural stem cells from differentiated somatic cells. The present disclosure also provides induced neural stem cells generated using a subject method, as well as differentiated cells generated from a subject induced neural stem cell. A subject neural stem cell, as well as differentiated cells derived from a subject neural stem cell, is useful in various applications, which are also provided in the present disclosure.

公开(公告)号：EP3105315A4

公开(公告)日：2017-07-12

申请号：EP15748953

申请日：2015-02-04

Applicant: BEIHAO STEM CELL AND REGENERATIVE MEDICINE TRANSLATION RES INST ,  UNIV BEIJING ,  BEIJING VITALSTAR BIOTECHNOLOGY CO LTD

Inventor： DENG HONGKUI ,  DU YUANYUAN ,  SHI YAN ,  JIA JUN ,  WANG JINLIN ,  XIANG CHENGANG ,  SONG NAN ,  XU JUN ,  YIN MING

IPC: C12N5/0735 ,  A61K35/407 ,  A61K48/00 ,  A61P1/16 ,  C12N5/071 ,  C12N5/10

CPC classification number: C12N5/067 ,  A61K35/407 ,  C12N2501/40 ,  C12N2501/60 ,  C12N2501/606 ,  C12N2506/13 ,  C12N2506/1307 ,  C12N2510/00

Abstract: A method for inducing reprogramming of a cell of a first type which is not a non-hepatocyte (non-hepatocyte cell), into a cell with functional hepatic drug metabolizing and transporting capabilities, is disclosed. The non-hepatocyte is induced to express or overexpress hepatic fate conversion and maturation factors, cultured in somatic cell culture medium, hepatocyte cell culture medium and hepatocyte maturation medium for a sufficient period of time to convert the non-hepatocyte cell into a cell with hepatocyte-like properties. The iHeps induced according to the methods disclosed herein are functional induced hepatocytes (iHeps) in that they express I and II drug-metabolizing enzymes and phase III drug transporters and show superior drug metabolizing activity compared to iHeps obtained by prior art methods. The iHeps thus provide a cell resource for pharmaceutical applications.

Abstract translation: 公开了一种诱导非非肝细胞（非肝细胞）的第一类细胞重编程为具有功能性肝药物代谢和转运能力的细胞的方法。 诱导非肝细胞表达或过表达肝转化和成熟因子，在体细胞培养基，肝细胞培养基和肝细胞成熟培养基中培养足够的时间以将非肝细胞转化为具有肝细胞的细胞 像属性。 根据本文公开的方法诱导的iHeps是功能诱导的肝细胞（iHeps），因为它们表达I和II药物代谢酶和III期药物转运蛋白，并且与通过现有技术方法获得的iHeps相比显示出优良的药物代谢活性。 iHeps因此为制药应用提供细胞资源。